A novel biomarker signature combining PAF and CME predicts chronic pain risk, linking brain activity to individual pain sensitivity and treatment strategies.
A novel biomarker signature combining PAF and CME predicts chronic pain risk, linking brain activity to individual pain sensitivity and treatment strategies.